APT Therapeutics’ Apyrase-Based Investigational Drug Minimizes Damage from Heart Attack without Increasing Hemorrhage Business Wire via Yahoo! Finance Oct 02 02:21pm APT Therapeutics, Inc. is developing an investigational new drug, APT102, for heart attack and stroke patients. According to a recent study published in Science Translational Medicine, APT102 maintained optimal blood flow and reduced damage to the heart muscle by 80% in animal model studies of heart attack.
Market Data 
Markets 
AI
